Advertisement
Journal Home
Search for

Volume 55, Issue 3, Pages 247-255 (May 2010)


View previous. 5 of 10 View next.

Orbital Involvement in Castleman Disease

Ioannis Venizelos, PhD1, Thomas G. Papathomas, MD1Corresponding Author Informationemail address, Maria Papathanasiou, MD2, Angeliki Cheva, MD1, Vasilia Garypidou, PhD2, Sarah Coupland, MBBS, PhD, FRCPath3

published online 13 January 2010.

Abstract 

Castleman disease is a quite uncommon lymphoproliferative disorder usually occurring in the lymph nodes. Rarely, Castleman disease develops in an extranodal anatomic location. We report on the first biopsy-proven case of multicentric plasma cell type of Castleman disease involving the orbital areas in a human herpes virus 8 (HHV-8)-unassociated/ human immunodeficiency virus (HIV)-seronegative 70-year-old man suffering from Parkinson disease. The diagnosis was established on the basis of morphologic, immunophenotypic, and molecular findings of a lymph node and orbital soft tissue biopsy. We additionally provide a review of all previously published cases of Castleman disease with an orbital involvement, discussing the distinctive characteristics and potential associations with regard to their counterparts at other sites. Although Castleman disease involving the orbit is an exceptionally rare occurrence that may present initially with ocular signs and symptoms, this should be included in the complete differential diagnosis of orbital mass lesion.

Stefan Seregard and Milton Boniuk, Editors

1 Department of Pathology, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece

2 Hematology Section, 2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece

3 Department of Cellular and Molecular Pathology, Royal Liverpool University Hospital, Liverpool, UK

Corresponding Author InformationReprint address: Thomas G. Papathomas, MD, 12 Kerkiras Str. (Kalamaria), Thessaloniki, GR-55133, Greece.

 The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

PII: S0039-6257(09)00262-8

doi:10.1016/j.survophthal.2009.09.003


View previous. 5 of 10 View next.

Advertisement